ReviewFrontiers in bioscience (Scholar edition)2010
Stem cells as potential therapeutic targets for inflammatory bowel disease.
Review in Frontiers in bioscience (Scholar edition), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Establishment of anMethodsX · 2024Article
- Article
- Cell membrane and bioactive factors derived from mesenchymal stromal cells: Cell-free based therapy for inflammatory bowel diseases.World journal of stem cells · 2019Review
- Intercellular adhesion molecule-1 enhances the therapeutic effects of MSCs in a dextran sulfate sodium-induced colitis models by promoting MSCs homing to murine colons and spleens.Stem cell research & therapy · 2019Article
- Review
- PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice.American journal of translational research · 2019Article
- Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.Stem cell research & therapy · 2018Article
- Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients.Oncotarget · 2018Article
- Circulating Endothelial Progenitor Cells in Crohn's Disease: An EPiC in the Making?Digestive diseases and sciences · 2017Article
- Allogeneic guinea pig mesenchymal stem cells ameliorate neurological changes in experimental colitis.Stem cell research & therapy · 2015Article
- Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact.Stem cell research & therapy · 2015Article
- Are stem cells a potential therapeutic tool in coeliac disease?Cellular and molecular life sciences : CMLS · 2015Review
- Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice.Journal of translational medicine · 2014Article
- Surgical treatment of perianal fistulizing Crohn's disease: from lay-open to cell-based therapy--an overview.TheScientificWorldJournal · 2014Review
- Granulomas of intestinal tuberculosis and Crohn's disease can be differentiated by CD73 cell surface marker expression: a pilot study.Digestive diseases and sciences · 2013Article
- Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors.Mediators of inflammation · 2013Review
- Physiological and pathological role of local and immigrating colonic stem cells.World journal of gastroenterology · 2012Review
- Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.Inflammatory bowel diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The incidence and prevalence of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), are rising. According to some estimates >1 million new cases of IBD arise in the United States annually. The conventional therapies available for IBD range from anti-inflammatory drugs to immunosuppressive agents, but these therapies generally fail to achieve satisfactory results due to their side effects. Interest in a new therapeutic option, that is, biological therapy, has gained much momentum recently due to its focus on different stages of the inflammatory process. Stem cell (SC) research has become a new direction for IBD therapy due to our recent understanding of cell populations involved in the pathogenic process. To this end, hematopoietic and mesenchymal stem cells are receiving more attention from IBD investigators. The intestinal environment, with its crypts and niches, supports incoming embryonic and hematopoietic stem cells and allows them to engraft and differentiate. The above findings suggest that, in the future, SC-based therapy will be a promising alternative to conventional therapy for IBD. In this review, we discuss SCs as potential therapeutic targets for future treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.